[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11202106764YA - Anti-ctla-4 binding proteins and methods of use thereof - Google Patents

Anti-ctla-4 binding proteins and methods of use thereof

Info

Publication number
SG11202106764YA
SG11202106764YA SG11202106764YA SG11202106764YA SG11202106764YA SG 11202106764Y A SG11202106764Y A SG 11202106764YA SG 11202106764Y A SG11202106764Y A SG 11202106764YA SG 11202106764Y A SG11202106764Y A SG 11202106764YA SG 11202106764Y A SG11202106764Y A SG 11202106764YA
Authority
SG
Singapore
Prior art keywords
ctla
methods
binding proteins
proteins
binding
Prior art date
Application number
SG11202106764YA
Inventor
David Johnson
Adam Adler
Rena Mizrahi
Yoong Lim
Michael Asensio
Erica Stone
Original Assignee
Gigagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gigagen Inc filed Critical Gigagen Inc
Publication of SG11202106764YA publication Critical patent/SG11202106764YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202106764YA 2018-12-27 2019-12-27 Anti-ctla-4 binding proteins and methods of use thereof SG11202106764YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862785659P 2018-12-27 2018-12-27
PCT/US2019/068820 WO2020140084A1 (en) 2018-12-27 2019-12-27 Anti-ctla-4 binding proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11202106764YA true SG11202106764YA (en) 2021-07-29

Family

ID=71126610

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106764YA SG11202106764YA (en) 2018-12-27 2019-12-27 Anti-ctla-4 binding proteins and methods of use thereof

Country Status (12)

Country Link
US (1) US20220064303A1 (en)
EP (1) EP3902821A4 (en)
JP (2) JP7558949B2 (en)
KR (1) KR20210121045A (en)
CN (1) CN114008071B (en)
AU (1) AU2019413366A1 (en)
BR (1) BR112021012588A2 (en)
CA (1) CA3124961A1 (en)
IL (2) IL284156B1 (en)
MX (1) MX2021007848A (en)
SG (1) SG11202106764YA (en)
WO (1) WO2020140084A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ742290A (en) * 2015-10-23 2019-11-29 Merus Nv Binding molecules that inhibit cancer growth
EP4175981A4 (en) * 2020-07-02 2024-07-24 Gigagen, Inc. ANTI-CTLA-4 BINDING PROTEINS AND METHODS OF USE THEREOF
WO2022147222A1 (en) * 2020-12-31 2022-07-07 Novarock Biotherapeutics, Ltd. Antibodies to tnfr2 and uses thereof
MX2023014836A (en) * 2021-07-02 2024-02-06 Gigagen Inc Anti-ctla-4 binding proteins and methods of use thereof.
WO2023108114A2 (en) * 2021-12-10 2023-06-15 Merck Sharp & Dohme Llc Human mesothelin binders
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
TWI320716B (en) * 2002-10-14 2010-02-21 Abbott Lab Erythropoietin receptor binding antibodies
EP1793858A4 (en) * 2004-09-08 2008-12-10 Univ Ohio State Res Found ANTI-CTLA4 HUMAN MONOCLONAL ANTIBODIES FOR THE TREATMENT OF CANCER
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
DK2925350T3 (en) * 2012-12-03 2019-05-13 Bristol Myers Squibb Co INCREASING THE BUSINESS AGAINST CANCER OF IMMUNOMODULATORY FC-MUSIC PROTEINS
KR101923326B1 (en) * 2014-06-06 2018-11-29 브리스톨-마이어스 스큅 컴퍼니 Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
EP3256165B1 (en) * 2015-02-13 2021-07-14 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
BR112017025564B8 (en) * 2015-05-29 2022-01-04 Agenus Inc Anti-ctla-4 antibodies and methods of using them
AU2016370648B2 (en) * 2015-12-15 2023-03-09 OncoC4, Inc. Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
SG10201603721TA (en) * 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
NL2017270B1 (en) * 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
IL312337A (en) * 2017-05-19 2024-06-01 Wuxi Biologics Shanghai Co Ltd Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), preparations containing them and uses thereof

Also Published As

Publication number Publication date
WO2020140084A1 (en) 2020-07-02
JP2022516071A (en) 2022-02-24
EP3902821A1 (en) 2021-11-03
BR112021012588A2 (en) 2021-09-08
AU2019413366A1 (en) 2021-08-12
KR20210121045A (en) 2021-10-07
MX2021007848A (en) 2021-10-26
CN114008071A (en) 2022-02-01
IL284156B1 (en) 2024-12-01
JP2024042072A (en) 2024-03-27
US20220064303A1 (en) 2022-03-03
JP7558949B2 (en) 2024-10-01
IL284156A (en) 2021-08-31
CA3124961A1 (en) 2020-07-02
IL316757A (en) 2025-01-01
CN114008071B (en) 2025-01-21
EP3902821A4 (en) 2022-11-30

Similar Documents

Publication Publication Date Title
IL281783A (en) Sirpα binding proteins and methods of use thereof
IL275782A (en) Multispecific antigen binding proteins and methods of use thereof
SG11202103022WA (en) Dll3 binding proteins and methods of use
IL288071A (en) Epcam binding proteins and methods of use
IL276731A (en) Anti-cd73 antibodies and methods of use thereof
IL264211A (en) Multispecific antigen binding proteins and methods of use thereof
IL261666A (en) Binding proteins and methods of use thereof
IL278821A (en) Anti-sirpa antibodies and methods of use thereof
EP3635013A4 (en) Nectin-4 binding proteins and methods of use thereof
SG11202010909RA (en) Anti-msr1 antibodies and methods of use thereof
IL284156A (en) Anti-ctla-4 binding proteins and methods of use thereof
IL279201A (en) Multi-specific binding proteins and methods of use thereof
IL284157A (en) Anti-pd-1 binding proteins and methods of use thereof
ZA202300348B (en) Anti-sortilin antibodies and methods of use thereof
IL279648A (en) Anti-sirp-beta1 antibodies and methods of use thereof
IL283884A (en) Anti-il-36 antibodies and methods of use thereof
IL280338A (en) Anti-siglec-5 antibodies and methods of use thereof
IL284364A (en) Anti-pd-l1 binding proteins and methods of use thereof
IL279227A (en) Anti-siglec-7 antibodies and methods of use thereof
IL308973A (en) Anti-ctla-4 binding proteins and methods of use thereof